Oral oxymetholone reduces mortality induced by gamma irradiation in mice through stimulation of hematopoietic cells
- 101 Downloads
Oxymetholone is a 17α -alkylated anabolic-androgenic steroid. This drug can stimulate bone marrow cells and increase the blood cells in the peripheral blood vessels. It has been used for the treatment of anemia caused by low red cell production. Since oxymetholone has hematopoietic effect, we studied radioprotective effects of this drug in mice. In this study, we determined percentage of survival, dose-reduction factor (DRF) and hematological parameters in irradiated mice which treated with or without oxymetholone. Oxymetholone administrated at different doses 80, 160, 320, 640 mg/kg by gavages at 24 h before 8 Gy gamma irradiation. At 30 days after treatment, the following percentage of animals survival in each group was as: 80 mg/kg, 50%; 160 mg/kg, 50%; 320 mg/kg, 55%; 640 mg/kg, 75% and vehicle, 15%. Percentage of survival increased in all of treated groups statistically compared with irradiated-vehicle group. In the groups treated by oxymetholone, maximum protection was realized at 640 mg/kg. In order to calculate the DRF for oxymetholone, mice were exposed to whole-body gamma irradiation with dose ranges between 5.83 and 11.23 Gy. The probit line for oxymetholone-treated mice was shifted to the right with a DRF of 1.14. In mice exposed to whole-body gamma-irradiation (4 Gy), an oral administration of 640 mg/kg oxymetholone ameliorated radiation-induced decreases in circulating platelets and erythrocytes, but had a less effect on total number of WBC. These results demonstrate that oxymetholone stimulates myelopoiesis and thrombocytopenia and enhances survival in mice after ionizing radiation.
Keywordsradioprotective oxymetholone hematopoietic survival radiation
Unable to display preview. Download preview PDF.
- 3.Drouet M, Mourcin F, Grenier N, Leroux V, Denis J, Mayol JF, Thullier P, Lataillade JJ, Herodin F: Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates frommyelosuppresion: long-term follow-up. Blood 103: 878–885, 2004PubMedCrossRefGoogle Scholar
- 4.Farese AM, Hunt P, Grab LB, MacVittie TJ: Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.J Clin Invest 97: 2145–2151, 1996PubMedCrossRefGoogle Scholar
- 7.Jagetia GC, Baliga MS, Venkatesh P, Ulloor JN: Influence of ginger rhizome (Zingiber officinalis Rosc) on survival, glutathione and lipid peroxidation in mice after whole-body exposure to gamma radiation. RadiatRes 160: 584–592, 2003Google Scholar
- 11.Bolton S: Statistical inference: estimation and hypothesis testing In: Pharmaceutical Statistics Practical and Clinical Applications 3th Edition,Eds. J. Swarbrick, Inc, Marcel Dekker, New York, pp.162–178, 1997Google Scholar
- 15.Lord B., Hendry, JH: Radiation toxicology: bone marrow and leukemia. In: Radiation toxicology: bone marrow and leukemia. (J. H. Lord, Eds), Taylor& Francis, London, pp. 1–21, 1995Google Scholar
- 16.Patchen ML: Single and combination cytokine therapies for the treatmentof radiation-induced hematopoietic injury. Adv Biosci 94: 21–36, 1996Google Scholar
- 24.National Toxicology Program.: NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech RepSer 485: 1–233, 1995Google Scholar